TG Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 11/28/2023
TG Therapeutics Stock Forecast and Price Target
The average price target for TG Therapeutics's stock set by recognized analysts recently is $24.00, which would result in a potential upside of approximately 90.02% if it reached this mark. The estimation is based on a high estimate of $41.00 and a low estimate of $6.00. If you're interested in TGTX stock, it's important to compare it to other companies in the industry.
90.02% Upside
TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
TG Therapeutics's Price has grown In the last three years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $12.75 – an increase of 100.00%. For the next eight years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Outperform |
9
|
CHF86.00 | Buy/Sell | CHF103.75 | 17.87% |
| SAN Stock Forecast | Sanofi | Outperform |
13
|
85.76€ | Buy/Sell | 108.44€ | 22.43% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
| MRK Stock Forecast | Merck KGaA | Buy |
17
|
157.80€ | Buy/Sell | 204.63€ | 18.19% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
30.56€ | Buy/Sell | 55.86€ | 60.34% |
TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030
TG Therapeutics's Revenue has grown In the last three years, rising from $150.00k to $2.79M – a growth of 1760.00%. In the next year, analysts believe that Revenue will reach $229.47M – an increase of 8124.73%. For the next eight years, experts predict that TG Therapeutics's Revenue will grow at a rate of 61921.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$227.41 | Buy/Sell | $322.44 | 36.76% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.14k | Buy/Sell | kr2.84k | 29.67% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Hold |
12
|
$9.80 | Buy/Sell | $12.04 | 9.69% |
.jpg)
TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-176.18M – an increase of 32.53%. 3 analysts predict TG Therapeutics's Free Cash Flow will decrease by 122.15% in the next year, reaching $39.03M. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 573.89%, to $834.90M.
TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's Net Income has grown by 14.73%, rising from $-172.87M to $-198.34M. In the following year, 7 experts forecast that TG Therapeutics's Net Income will decrease by 105.05%, to $10.02M. In 2030, professionals predict that TG Therapeutics's Net Income will decrease by 644.19%, to $1.08B.
TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-192.54M. This represents a growth of 13.96%. For the following year, the 3 analysts predict that TG Therapeutics's EBITDA will drop by 104.12%, reaching $7.93M. Over the next eight years, experts predict that TG Therapeutics's EBITDA will grow at a rate of 32.66%.
TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030
TG Therapeutics's EBIT has seen growth In the last three years, going from $-169.06M to $-192.84M – a gain of 14.07% In the following year, the 8 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 106.58%, reaching $12.69M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 688.99%, falling down to $1.14B.
TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, TG Therapeutics's EPS has gone down from $-1.96 to $-1.46 – a 25.51% drop. In the next year, 7 analysts estimate that TG Therapeutics's EPS will decrease by 101.37%, reaching $0.02. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 539.73%, reaching $6.42.
.jpg)